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Abstract 
Introduction: The gold standard to assess the presence and severity of portal 
hypertension remains the hepatic vein pressure gradient, however the recent 
development of non-invasive assessment using elastography techniques offers 
valuable alternatives. In this review, we discuss the diagnostic accuracy and utility of 
such techniques in patients with portal hypertension due to cirrhosis. 
Areas covered: A literature search focused on liver and spleen stiffness 
measurement with different elastographic techniques for the assessment of the 
presence and severity of portal hypertension and oesophageal varices in people with 
chronic liver disease. The combination of elastography with parameters such as 
platelet count and spleen size is also discussed. 
Expert commentary: Non-invasive assessment of liver fibrosis and portal 
hypertension is a validated tool for the diagnosis and follow-up of patients. Baveno 
VI recommended the combination of transient elastography and platelet count for 
ruling out varices needing treatment in patients with compensated advanced chronic 
liver disease. Assessment of aetiology specific cut-offs for ruling in and ruling out 
clinically significant portal hypertension is an unmet clinical need. The incorporation 
of spleen stiffness measurements in non-invasive algorithms using validated 
software and improved measuring scales might enhance the non-invasive diagnosis 
of portal hypertension in the next five years. 
Keywords: Varices; Baveno; Fibroscan; ARFI; Spleen stiffness; HVPG 
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1) Introduction 
Portal hypertension (PH) is a clinical syndrome characterised by a combination of 
increased resistance to blood flow in the portal venous system and/or its tributaries 
and endothelial dysfunction. Cirrhosis is the most common cause of intrahepatic 
sinusoidal PH.PHin cirrhosisdevelops as a consequence of structural changes of 
liver parenchyma due to inflammation, collagen deposition, nodule formation and 
vascular occlusion/remodelling. This “static” component causes the initial vascular 
modifications responsible of increasing portal pressure. Nevertheless about 1/3 is 
caused by a functional “dynamic” component[1, 2]. Porto-systemic collaterals 
develop as a consequence of the high pressure in the portal vein. However, even 
when portal blood flow is entirely diverted through collaterals, PH persists because of 
a concomitant increase in portal venous inflow, which in turn is caused by splanchnic 
vasodilatation[3]. This mechanism leads to further and progressive increase in PHthe 
relevance of which derives from its complications: formation of oesophageal or 
gastric varices, variceal bleeding, ascites, spontaneous bacterial peritonitis, 
hepatorenal syndrome, porto-pulmonary hypertension, hepatic encephalopathy, 
portal hypertensive gastropathy, enteropathy and altered metabolism of endo- and 
xenobiotics normally metabolised by the liver[4]. The most important collaterals are 
gastro-esophageal varices since they represent a “marker” of PHon routine 
endoscopy screening and because they potentially can rupture leading to life 
threatening bleeding. 
The gold standard to assess the presence and severity of PHremains the hepatic 
venous pressure gradient (HVPG), however the recent development of non-invasive 
assessment using elastography techniques offers valuable alternatives. In this 
review, we discuss the diagnostic accuracy and utility of such techniques in patients 
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with established chronic liver disease. The use of these techniques in non-cirrhotic 
portal hypertension is outside the scope of this review. 
2) Assessment of pH 
a) HVPG and endoscopy 
Gastroscopy as a screening test for varices is routinely offered once the diagnosis of 
cirrhosis is confirmed because of its excellent diagnostic accuracy and potential 
therapeutic approach. Once the presence of gastro-esophageal varices is confirmed, 
medical or endoscopic treatment and subsequent follow up istailored depending on 
the size of varices, presence of wale marks and severity of underlying liver disease 
that determine the risk of bleeding [5, 6]. However, although endoscopy is obviously 
an important procedure to be carried out because of both diagnostic and therapeutic 
applications, the most important diagnostic investigation for PH is the HVPG 
measurement. The relationship between wedge and free hepatic venous pressure is 
able to provide important clues on the underlying site of resistance and hence allow 
an appropriate diagnosis of what is causing the increase in portal pressure. 
Moreover, HVPG is directly proportional to the severity of PHin cirrhosis and 
therefore, it is considered the most important predictor of clinical outcome in chronic 
liver disease [7-11]. An HVPG of ≥10 mmHg defines clinically significant PH (CSPH) 
because is independently associated with an increased risk of decompensation [12] 
and development of hepatocellular carcinoma (HCC) [13]. 
b) Elastography 
Over the last years, the assessment of liver disease has improved substantiallydue 
to theintroduction of elastography. The possibility toestimate liver fibrosis and 
indirectly the severity of PH[14]by measuring liver stiffness (LS) has changed patient 
management; liver elastography is now routinely used in the clinical evaluation of 
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patients with chronic liver disease [15, 16].The use of elastography in clinical 
practice is based on the rationale that an applied force to a certain tissue will induce 
a parenchymal displacement,the entity of which is related to the tissue 
characteristics and properties. By measuring the speed of displacement, 
elastography enables to measure the parenchymal biomechanical properties that in 
liver disease are modified as a consequence of collagen deposition. Although the 
presence of fibrosis is the main determinant of increased stiffness, “confounding” 
factors might contribute or might even drive independently LS by increasing 
intrahepatic pressure (cholestasis, congestion, inflammation, food intake).  
The rationale that brought to use LS measurement as an expression of PH is based 
on the fact that LS depends on the amount of collagen and therefore the mechanical 
“static”component of portal pressure. With the progression of liver disease, extra-
hepatic factors contribute to further increase in portal pressure. These are mainly 
vasoactive molecules that act by inducing intra-hepatic vasoconstriction and 
splanchnic vasodilation hence increasing portal pressure independently from the 
amount of collagen deposition. Therefore, as PH becomes more severe, the 
correlation between LS and HVPG is lost, as demonstrated by Vizzuti, et al.[17], 
because the factors which contribute to the further increase in portal pressure go 
beyond the amount of fibrosis. In such cases, the measurement of spleen stiffness 
(SS) seems to be a more reliable marker of PH as well as predictor of hepatic 
decompensation. The portal vein receives blood from the splenic vein, hence any 
increase in portal pressure is theoretically transmitted to the spleen with a 
subsequent increase in intrasplenic pressure and related increased stiffness.   
The European Federation of Societies for Ultrasound in Medicine and Biology 
(EFSUMB) issued guidelines regarding the clinical application of elastography [18-
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20]. According to these guidelines, ultrasound based-elastographic techniques are 
classified in: strain techniques and shear wave elastography techniques. The last 
category includes transient elastography (TE), point shear wave elastography 
(pSWE) and shear wave elastography (SWE) imaging (including 2D-SWE and 3D-
SWE).  
3) Elastography for the assessment of HVPG 
a) Liver Stiffness 
TEwas the first elastographic method introduced to assess LSwith the objective 
toestimate liver fibrosis. Published meta-analysis of studies on TE validation 
compared toliver biopsy demonstratea good diagnostic accuracy for staging fibrosis 
in chronic liver disease with different cut-off values according to aetiology [15, 16, 
21-23].  
Many studies, summarized in table 1, have been published so far regarding the 
correlation between TE measurement and HVPG and 12 of them have been 
included in a recent meta-analysis aimed to evaluate the diagnostic performance of 
LS-TE for CSPH[17, 24-35]. Eight studies were prospective and four retrospective 
with a total sample size of 1491 patients. Among these studies, 10 provided 
information on both the correlation between TE and HVPG values and the diagnostic 
performance ofLS-TE in specifically detecting CSPH. 
The summary correlation coefficient was 0.783 (95% CI, 0.737-0.823), suggesting a 
reasonable correlation between liver stiffness and HVPG. However, this correlation 
seems to become poor for high values of HVPG (HVPG>12 mmHg), probably 
because of the increasing relevance of extra-hepatic factors influencing the 
progression of PH[36]. A summary sensitivity and specificity of 87% (95%CI 76-94%) 
and 85% (95%CI, 77-91%), respectively, indicates a good diagnostic performance of 
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LS-TE to diagnose CSPH, with a cut-off value widely ranging from 8.74 kPa to 25 
kPa and an AUROC of 0.90.  
This wide range of cut-offsis partly due to an outlier study that included patients 
without CSPH [27]. An additional reason could be the heterogeneous aetiology, with 
a high number of ALD and NASH patients possibly having a significant inflammatory 
component, and the variable inclusion of patients with advanced/decompensated 
liver disease. 
Abraldes et al. studied a population of 518 patients with compensated advanced 
chronic liver disease of different aetiology and showed that simple parameters such 
as LS by TE, platelet count and spleen diameter in different combinations, can 
identify up to 80% of patients with CSPH. This allows the clinician to reliably predict 
which patients have a very high risk of CSPH, thus allowing an early, non-invasive 
identification of patients at higher risk of developing decompensation [37].  
Even though these results are encouraging, the heterogeneity of the studied 
populations, the relatively small number of available data and the lack of prospective 
studies with predefined cut-offs represent important limitation factors in terms of 
overall accuracy.  
Among pSWE techniques, acoustic radiation force imaging (ARFI) has been widely 
used. Although ARFI represents a valid tool to diagnose liver cirrhosis in comparison 
to TE, there is only one study that evaluated the usefulness of ARFI elastography as 
a predictor of CSPHin 78 patients who underwent HVPG measurement [38]. The LS 
values were significantly higher in CSPH, with a high diagnostic performance of 
ARFI (AUC 0.93). However, even in this study the population was very 
heterogeneous in terms of aetiology, hence raising concerns on its reliability and 
application in clinical practice on a larger scale.  
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Different studies have been published on the diagnostic performance of LS 
measured by the 2D-SWE technique of Supersonic imaging (SSI) in the assessment 
of PH compared to HVPG measurement. According to the published results, SSI 
represents a very good tool in diagnosing CSPH and severe PH (SPH), with 
sensitivity, specificity and cut-off values ranging from 81% to 90.5%, 80% to 89.5% 
and 15.2 kPa to 24.5 kPa, respectively [39-41]. 
Jansen et al [42] adopted dual cut-offs (rule-in and rule-out) to reach a better 
performance; one third of patients (48/155) were in the unclassified range and would 
need to undergo HVPG to be correctly diagnosed. Probably, this is due to the high 
number of patient with alcoholic liver disease (ALD) and NASH (53% and 17%, 
respectively) compared to other studies.    
No data are available regarding the predictive value of ElastPQ techniques for PH 
measured by HVPG.  
Moreover, LS seems to have a better diagnostic performance for CSPH when used 
alone than when integrated with spleen size and platelets count (LSPS) (AUC 0.87 
and 0.76, respectively) [40, 41]. This may be due to the non-linear relationship 
between spleen size and PH. Although the pathogenic mechanisms causing spleen 
enlargement in patients with PH are still not completely understood, splenomegaly is 
not a simple increase of spleen size due to passive congestion development, but 
also to lymphoid hyperplasia, angiogenesis and fibrogenesis. For this reason, even if 
splenomegaly represents a very frequent finding in patients with PH, its clinical utility 
is controversial and spleen parameters non-invasively assessed as spleen size and 
area have not been widely developed and pursued.   
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b) Spleen Stiffness 
Fourstudies (Table 2) prospectively evaluated the correlation between SS measured 
with TE and PH assessed by HVPG [28, 36, 40]. However, in one of them [36] the 
authors only reported the correlation between the two techniques (r=0.433), without 
giving data on the performance of SS in predicting CSPH. Moreover, this correlation 
was not significant for HVPG>19 mmHg, reflecting the fact that SS does not have a 
linear correlation with HVPG when PH is more severe.  
Data regarding the diagnostic performance of TE-SS in predicting CSPH and SPH 
are quite controversial. TE-SS had a good performance in the studies by Zykus, et 
al. [43] and Colecchia, et al [28]. However, in the latter the authors had to use rule-in 
and rule-out cut-off values to get a better sensitivity and specificity, with a widerange 
of unclassified patients. TE-SS had a poor diagnostic performance in the study of 
Elkrief, et al.[40]. This discrepancy may be explained by the presence of a high 
number of patients with decompensated liver disease and more severe PH in the 
population enrolled in this studywith respect to those of Zykus and Colecchia (Child-
Pugh C44%, 0.9% and 0%, respectively; median HVPG 17 mmHg, 14 and 12 
mmHg, respectively).  
It is important to mention that the number of non-reliable/failed SS assessments with 
TE is higher compared to those of LS. This is due to technical issuesmainly caused 
bysmall sizedspleens and represents an important limitation. In addition, a 
conventional ultrasound device is usually needed to locate the spleen. 
There is only one study that evaluated the diagnostic performance of ARFI in 
patients who underwent an invasive measurement of portal pressure [38]. 
The performance of SS using ARFI in assessing both SPH and CSPH was better 
than TE in this study that included a significant proportion of patients with 
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decompensated liver disease and high HVPG values (Child-Pugh C 18%, median 
HVPG 18 mmHg). Importantly, no SS assessment failureswere reported. This is due 
to the fact that ARFI is an elastographic technique integrated in an ultrasound 
system, which allows scanperformance even in patients with high BMI, ascites or a 
small spleen.  
Data about the diagnostic performance of SSI were controversial in two studies with 
heterogeneous populations regarding the severity of liver disease[40]. Similarly to 
ARFI, SSI is better than TE in measuring SS. Although the use of rule-in and rule-out 
cut-off values results in better diagnostic performance, the number of patients in the 
unclassified range is high (41%)[42] 
No data are available regarding the predictive value of ElastPQ techniques for PH 
measured by HVPG.   
4) Elastography for the assessment of oesophageal varices (EV) 
a. Liver Stiffness 
Many studies (Table 3) have been published showing the usefulness of TE-LS in 
predicting the presence of EV and large EV assessed by upper gastrointestinal 
endoscopy (UGI-endoscopy). Fifteen of thesestudies have been included in a recent 
meta-analysis which included a total of 2697 patients[44]. The summary sensitivity, 
specificity and AUROC were 84%, 62% and 0.82, respectively, for the detection of 
EV. TE-LS diagnosed the presence of large EV with a summary sensitivity, 
specificity and AUROC of 78%, 76% and 0.82, respectively. The cut-off values range 
was 12 kPa-29.7 kPa and 19 kPa-48 kPa for EV and large EV, respectively.  
A meta-regression and subgroup analysis showed that the aetiology of liver disease 
represents the reason of this wide heterogeneity only in the EV group, with lower cut-
off values in viral aetiology and higher in alcoholic cirrhosis. Similar results have 
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been shown by two meta-analyses published in 2016[45, 46]. Therefore LS on its 
own cannot reliably diagnose or rule out varices of any size or varices needing 
treatment. 
In 2010 Kim et al found significant differences in LS, spleen diameter and platelet 
count between patients with and without EVs. Accordingly, they developed a LS-
spleen diameter to platelet count ratio score (LSPS), which showed a good reliability 
and performance for detection of EVs[47]. In 2013, Berzigotti et al confirmed that the 
accuracy to non-invasively assess PH improved by combining LS, spleen size and 
platelet count. LSPS score showed a very good correlation with CSPH evaluatednot 
only by the presence of EVs at endoscopy but also by HVPG[48].  
In 2014 Augustin et al evaluated 250 patients and those with LS > 13.6 kPa 
underwent endoscopy and portal pressure measurement by HVPG. 90% of EVs 
detected by endoscopy belonged to the group of patients with platelet count 
<150.000, LS > 13.5 kPa and abnormal ultrasound (nodular profile and increased 
spleen size). A LS cut-off of 25 KPa was excellent at ruling-in CSPH[25]. 
A retrospective study conducted by Ding demonstrated that the combination of LS 
≤25 kPa and platelet count ≥ 100.000 could be used in clinical practice to exclude 
the presence of high-risk GOV in patients with Child-Pugh A cirrhosis [49]. 
On the basis of these results, during the Baveno VI Consensus Workshop, the 
combination of TE-LS and platelet count wasproposed as a non-invasive tool to rule 
out patients with compensated advanced chronic liver disease (cACLD) and Child 
Pugh A cirrhosis who can safely avoid screening endoscopy. In particular, patients 
with a liver stiffness<20 kPa and a platelet count >150,000 have a very low risk of 
having varices requiring treatment, and can avoid screening endoscopy. These 
patients can be followed up by yearly repetition of TE and platelet count. If the liver 
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stiffness increases or the platelet count declines, these patients should undergo 
screening endoscopy [37, 50-52]. Figure 1 is a graphic representation of the Baveno 
VI criteria. These criteria have been evaluated in multiple studies since 2015, which 
confirm that less than 5% of patients with varices needing treatment are missed 
[51](Table 4).However, implementation of the criteria spares just 20% of screening 
endoscopies.. 
For this reason, the Baveno VI criteria have recently been expanded with new 
criteria (Expanded-Baveno VI) in a study with a derivation and two additional 
validation cohorts from London (309 patients) and Barcelona (117 patients). The 
best new expanded classification rule was platelet count >110 x109 cells/L and LS 
<25 kPa. The Expanded-Baveno VI criteria would potentially spare 40% of 
endoscopies vs. only 21% using the original Baveno-VI criteria. These new criteria 
performed well in patients with compensated advanced chronic liver disease due to 
HCV, ALD and NASH [53]. 
b. Spleen Stiffness 
TE-SS alone or in combination with TE-LS and/or other parameters (i.e. laboratory, 
spleen size) represents a promising tool for predicting EV in patients with liver 
cirrhosis. Moreover, in some studies (Table 5) the diagnostic performance seems to 
be better than that of TE-LS. However, data regarding the strength of performance 
and cut-offsvary depending on the underlying aetiology and the Child Pugh stage of 
the enrolled patients. 
Although the data collected so far in this setting showed that TE is promising, the 
percentage of failures is higher when it is performed on the spleen compared to the 
liver, as already mentioned. Moreover, the upper limit cut-off value of 75 kPa 
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represents a further limitation, as SS often is higher than that value[28, 36, 54-58] 
(Table 5). 
SS measured by ARFI represents a more reliable technique to predict EVs and high-
risk EVs with a better performance compared to platelet count, spleen size and even 
LS in most studies[59-61]. Only one study reported no correlation between 
SSmeasured by ARFI and the presence or severity of EV, as well as the risk of 
variceal bleeding. However, the authors did not provide information about liver 
disease aetiology and severity[62].  
In a recent published prospective multicentre study, Jansen demonstrated that the 
diagnostic performance in detecting CSPH improved by combining LS and SS. Using 
a LS cut-off value of 38 kPa and SS cut-off value of 27.9 kPa, a total of 91.6% of 158 
patients were correctly classified with a sensitivity of 98.3% and specificity of 83.9% 
[42, 63]. This needs to be further validated in independent cohorts. 
 
5) Changes in elastography under non-selective betablockers and after tips 
Few papers have been published so far regarding the influence of non-selective 
beta-blockers (NSBBs) treatment on LS and SS.  
Reiberger et al investigated the correlation between LS and portal pressure in a 
cohort of 122 patients, with different aetiologies and Child-Pugh class stages (A:88, 
B:25, C:9). They showed that the correlation between LS measured by TE and 
HVPG was stronger in patients with HVPG<12 mmHg. The association of HVPG with 
LS in HVPG>12 mmHg became stronger under treatment with NSBBs, as this 
restored the linear correlation of HVPG and LS. The improvement in the correlation 
of LS and HVPG under NSBBs was predominantly in hemodynamic responders [32].  
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Similar results were obtained by Wong et al in a population of 144 patients (29 
receiving NSBBs and 35 with varices). They showed that the diagnostic performance 
of LS and SS assessed by TE in predicting varices was better in patients on NSBB 
treatment [58].  
These results confirm the increasing contribution of non-structural factors in severe 
PH and that LS and SS are not reliable in assessing the dynamic components of PH.  
Only two papers have been published about the influence of transjugular intra-
hepatic porto-systemic shunt (TIPS) placement on LS and SS measured by ARFI but 
in both the population size was very small. Gao et al investigated LS and SS 
modification after TIPS in 20 patients (10 healthy controls and 10 chronic hepatitis B 
patients with CSPH). There is no mention of the disease severity stage but all 
patients had a history of variceal bleeding and they underwent TIPS placement for 
CSPH treatment. In the results only SS seems to change after TIPS insertion and 
the authors conclude that it could be used as a marker in monitoring the TIPS 
function [64]. The study De Santis et al included 38 patients with different aetiologies 
and severity of disease stages. The indication for TIPS was variceal bleeding or 
refractory ascites. The results showed that although LS and SS were significantly 
modified by TIPS, SS decreased significantly more than LS and therefore seems to 
be superior in detecting the reduction of portal pressure induced by TIPS [65].  
 
 
7) Expert commentary 
Tissue stiffness is a biomechanical measurement that has become crucial for the 
clinical management of patients with chronic liver disease by providing predictive 
information not only on the severity of fibrosis, but also on PHand the risk of clinical 
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decompensation. The 2017 EFSUMB guidelines and recommendation for the clinical 
application of elastography highlighted recently the wide consensus on the use of 
different techniques for the diagnosis and staging of fibrosis, however existing data 
on PHis less extensive and there are still gaps to be filled. The most important 
change in clinical practice was provided by the latest Baveno VI recommendations, 
that suggested the combination of LS measurement (performed by TE) of <20 kPa 
with a platelet count >150,000 to rule out the presence of varices needing treatment 
in patients with cACLD, thus reducing unnecessary endoscopic screening. Although 
this is an important step in the management of patients with compensated cirrhosis, 
the current algorithm spares just 20% of the total number of endoscopies, with many 
procedure still carried out unnecessarily. Application of the recently published 
expanded Baveno VI criteria spares 40% of the total number of endoscopies and 
represents an important step forward.  These criteria need validation in patients with 
cholestatic liver disease and to a lesser extent in patients with NASH and alcohol-
related cirrhosis. Moreover, to date varices of any size cannot be diagnosed or ruled 
out non-invasively with reasonable diagnostic accuracy.  
As a principle, there are different aspects that need to be taken into account in the 
non-invasive assessment of chronic liver disease and the appraisal of existing data. 
Firstly,LS is relative to the result of the forces that interact within the hepatic 
parenchyma, while instead fibrosis is a histological diagnosis. Therefore, factors 
such as inflammation, congestion, obstructive jaundice and hepatic blood inflow 
influence stiffness potentially “simulating” fibrosis, overestimating its severity and 
hence the stiffness cut-off values for evaluating the presence of CSPH. 
Moreover different patterns of fibrosis and nodular formation that are aetiology-
specific in chronic liver disease have a different impact on the development of PH 
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and hence on the natural history of liver disease. Along these lines, a retrospective 
study evaluating the amount of fibrosis on explanted livers revealed that the amount 
of fibrosis measured by collagen proportional area was significantly different 
amongst different aetiologies of liver disease[66]. Therefore, it is likely that PH has a 
different onset according to the aetiology of liver disease and LS cut-off values are 
likely to follow these parenchymal modifications, which should be born in mind when 
performing a non-invasive assessment. For instance, patients with NASH are likely 
to develop PH even in pre-cirrhotic stages as shown in the study by Francque [67]. 
Therefore, specific disease characteristics, such as the large regenerative nodules 
particularly present in advanced hepatitis B, the inflammatory component of alcoholic 
liver disease, the pre-sinusoidal characteristics of PH in primary biliary cholangitis 
(PBC) and primary sclerosing cholangitis (PSC) and the technical issues to 
accurately measure LS in NASH represent a challenge for the standardisation of 
elastography measurements for the assessment of PH. Therefore, aetiology specific 
cut-offs for the assessment of PH need to be prospectively validated. 
Non-invasive assessment in NASH is particularly difficult. The majority of these 
patients have a high BMI and increased subcutaneous tissue thickness making the 
acquisition of reliable measurements technically challenging and this is only partially 
resolved with the XL probe.pSWE and 2D-SWE have the benefit of propagating a 
shear wave transversally within the hepatic parenchyma and in theory are less 
affected by the presence of thick subcutaneous tissue. Nevertheless in the presence 
of a severely steatotic/fibrotic liver in which there is a thick layer of subcutaneous 
adipose tissue and high posterior attenuation of the ultrasound beam, the region of 
interest is positioned deeper in the hepatic parenchyma, therefore there is a risk that 
the measurements acquired might be affected by these factors leading to reduced 
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accuracy. Another limitation of acquiring LS measurements in such patients is 
presence of intrahepatic artefacts as a consequence of reverberation from the 
abundant subcutaneous adipose tissue.  
Finally, with worsening PH, there is reduced correlation of LS with HVPG due to the 
increasing contribution of non-structural factors. This particular limitation can be 
partially overcome with the use of dual cut-offs for ruling in and ruling out CSPH, 
even though with this method there will be more than 30% of patients who does fit 
neither in the rule-in nor in the rule-out group.  
SS is an extremely promising extension of the use of elastography for the non-
invasive assessment of PH. Although there is limited data compared to LS, SS 
seems able to overcome the limitations of confounding factors that affect liver 
parenchyma and also to be a more objective marker of PH regardless of the 
underlying cause. In fact, if PH is typically characterised by increased resistance to 
portal flow and this reflects in increased intra-splenic pressure, targeting the latter 
should provide more accurate information for higher values of portal pressure. The 
available data is very encouraging in this respect, also because by measuring SS it 
is potentially possible to predict the presence of CSPH in patients with pre-hepatic 
PH, idiopathic PH and pre-sinusoidal PH where HVPG is misleading. 
8) Five-year view 
Although the recent EFSUMB recommendations for non-invasive assessment of PH 
provide some guidance, this cannot be applied indiscriminately. Currently, the target 
of elastography evaluation is the exclusion of large varices rather than the diagnosis 
ofthe severity of PH. Large cohort studies including populations differentiated by 
aetiology and sub-grouped according to severity of liver disease are warranted to 
establish reliable LS cut-off values for the prediction of CSPH, its severity, as well as 
D
ow
nl
oa
de
d 
by
 [U
CL
 L
ibr
ary
 Se
rv
ice
s] 
at 
07
:06
 08
 Se
pte
mb
er 
20
17
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
the risk of clinical decompensation. NASH related cirrhosis represents a true 
technical challenge and in consideration of its epidemiological burden the efforts of 
the hepatology community will need to concentrate in order to overcome the current 
limitations of the available techniques. PBC and PSC are both characterised by pre-
sinusoidal PH and LS is thought to underestimate the severity of fibrosis and PH. 
Moreover in PSC the increased LS might be due to cholestasis rather than fibrosis 
and there is no predictor of PH in these two conditions. SS measurements are likely 
to provide these answers and overcome the limitations of LS by information on intra-
splenic pressure. Nevertheless further standardisation of the technique is required 
and we expect over the next few years dedicated software that will improve its 
performance. Moreover the liver structural modifications accompanied by the 
splanchnic vascular changes that occur in liver disease suggest that the most 
accurate information on the diagnosis and severity of PH is provided by the coupled 
assessment of liver and spleen stiffness. Such algorithms are still awaited, but 
hopefully will be standardized in the next five years. 
 
9) Key issues 
• Portal hypertension represents a common complication of liver cirrhosis and it 
is the main driver of hepatic decompensation. 
• HVPG and upper-endoscopy represent the gold standard techniques to 
assess the presence of clinical significant portal hypertension and gastro-
oesophageal varices, respectively. 
• Liver and spleen stiffness measured with different elastography techniques 
show a good correlation with portal pressure assessed by HVPG and 
presence of oesophageal varices even though data are controversial about 
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sensitivity, specificity and cut-off values, probably due to the variability of the 
studied populations.   
• The Baveno VI and expanded Baveno VI criteria can be used to save 
unnecessary endoscopies for varices detection in patients with compensated 
advanced chronic liver disease since they have a very high negative 
predictive value for varices needing treatment. 
• Algorithms including both liver and spleen stiffness have a better diagnostic 
performance in ruling-in and out clinically significant portal hypertension, 
minimizing the number of misclassified patients. 
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Table 1. Diagnostic performance of different elastography techniques for detecting clinically significant PH. 
 CSPH 
STUDY, year Elastography Patients, n CP-C, n
NAFLD/ALD, 
n 
Cut-off value, 
kPa Sensitivity,% Specificity,% 
Augustin, 2014[25] TE 40 0 -/- 25 65 93 
Bureau, 2008[26] TE 150 21 11/51 21 90 93 
Carrion, 2006[27] TE 129 - 0/0 8.74 * 0 61 
Colecchia, 2012[28] TE 100 0 0/0 24.2 52 97 
Hong, 2013[29] TE 59 - 0/36 21.95 83 74 
Llop, 2012[31] TE 79 0 3/8 21 53 92 
Reiberger, 2012[32] TE 122 9 0/66 18 82 83 
Salzl, 2014[33] TE 59 - -/- 16.8 91 77 
Sanchez-Conde, 2011[34] TE 38 11 0/0 14 93 50 
Schwabl, 2014[35] TE 226 - -/31 16.1 95 87 
Vizzutti, 2008[17] TE 61 5 0/0 13.6 98 93 
Attia, 2015[38] ARFI 78 14 -/40 2.17** 97 89 
Jansen, 2016[42] SSI 158 14 27/89 24.2 68 80 
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Abbreviations: CP-C=Child-Pugh C; TE=transient elastography; ARFI=acoustic radiation force imaging; SSI=supersonic imaging; 
NAFLD=non-alcoholic fatty liver disease; ALD=alcoholic fatty liver disease; CSPH=clinical significant PH. 
* no patients with CSPH 
** m/sec 
 
 
 
 
 
 
 
Elkrief, 2015[40] SSI 79 35 6/33 24.5 81 88 
Procopet, 2015[39] SSI 88 - -/23 15.4 91 90 
Kim, 2015[41] SSI 92 11 -/56 15.2 86 80 
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Table 2. Diagnostic performance of splenic stiffness measured by elastography techniques  for detecting clinically 
significant PH. 
 CSPH 
STUDY, 
year 
Patients,
n 
Elastograp
hy  
CP-C, 
n 
NAFLD
/ALD, n
COV, 
kPa 
Se, % Sp, % Rule-in, 
kPa 
Se, % Sp, % Rule-out, 
kPa 
Se, % Sp,% 
Colecchia, 
2012[28] 100 TE 0 0/0    52.8 77 97 40 99 74 
Elkrief, 
2015[40] 79 TE 35 6/33 56.3 73 67       
Zykus, 
2015[43] 107 TE 1 -/19 47.6 77 79       
Elkrief, 
2015[40] 79 SSI 35 6/33 34.7 40 100       
Jansen, 
2016[42] 158 SSI 14 27/89 26.3 80 84 35.6 51 92 21.7 92 50 
Attia, 
2015[38] 78 ARFI 14 -/40 2.32* 96 89       
 
Abbreviations: CP-C=Child-Pugh C; TE=transient elastography; ARFI=acoustic radiation force imaging; NAFLD=non-alcoholic fatty 
liver disease;  ALD=alcoholic fatty liver disease; Se=sensitivity; Sp=specificity; CSPH=clinical significant PH. 
* m/sec 
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Table 3. Diagnostic performance of liver stiffness measured by elastography techniques for detecting oesophageal 
varices and large oesophageal varices. 
    Presence of EVs (grade 
0,1) 
Large EVs (grade 2,3) 
STUDY, year Patients, 
n 
Elastograp
hy 
CP-C, 
n 
NAFLD/ALD, 
n COV, kPa Se,% Sp,% 
COV, 
kPa Se,% Sp,% 
Sporea, 
2013[68] 
697 TE - 184    29.5 78 87 
Sharma, 
2013[36] 
174 TE 20 -/77 27.3 91 72    
Saad, 2013[69] 32 TE 0 0/0 29.7 95 67 38.2 100 77 
Nguyen-Khac, 
2010[70] 
183 TE 20 6/103    48 73 73 
Kazemi, 
2006[71] 
165 TE 0 -/9 13.9 95 43 19 91 60 
Jung, 2008[72] 112 TE - - 19.7 87 70    
Hu, 2015[73] 200 TE - 0/0 20.25 86 72 25.55 84 72 
Castera, 
2009[74] 
70 TE 0 0/0 21.5 76 78 30.5 77 85 
Calvaruso, 
2013[54] 
96 TE 0 0/0 17 71 57 19 72 55 
Bintintan, 
2015[75] 
60 TE 8 -/33 15 95 100 28.8 87 83 
Stefanescu, 
2011[56] 
137 TE 9 -/- 28 74 64    
Stefanescu, 
2011[76] 
231 TE 13 -/116 19 84 32 38 56 75 
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Wang, 2012[77] 126 TE 0 0 12 67 77 21 77 87 
Augustin, 2014 
[25] 
49 TE 0 -/- 25 80 72    
 
Abbreviations: NAFLD=non-alcoholic fatty liver disease; ALD=alcoholic liver disease;Se= sensitivity; Sp=specificity; COV=cut-off 
value; CP-C=Child-Pugh C; EVs=esophageal varices 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
o
w
n
l
o
a
d
e
d
 
b
y
 
[
U
C
L
 
L
i
b
r
a
r
y
 
S
e
r
v
i
c
e
s
]
 
a
t
 
0
7
:
0
6
 
0
8
 
S
e
p
t
e
m
b
e
r
 
2
0
1
7
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
Table 4. Summary of studies evaluating performance of Baveno VI criteria for screening endoscopy in patients with 
compensated advanced chronic liver disease.  
Study N Viral AL
D 
Varice
s 
VNT Varice
s 
misse
d§ 
VNT 
misse
d§ 
EGD 
spare
d& 
EGD 
unneede
d# 
Maurice[78] 310 55% 
13
% 
23% 5% 3.5% 0.6% 33% 48% 
Perazzo[79] 97 - - 54% 0 6% 0 22% 29% 
Llop[80] 161 85% - 16% 1.9% 1.9% 0 33.5% 53% 
Tossetti[81] 146 
100
% 
- 45% 8% 6% 0 27% 34% 
Jangouk[82] 262 71% 
13
% 
41% 
11.8
% 
- 0 22% - 
Chang [83] 173 55% - 31% 8% - 1.7% 20% - 
Thabut [84] 790 
100
% 
- - - 10% 0 20% - 
Paternostro [85] 135 47% 30 65% 24% 3% 0 7% 30% 
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N: Total number of patients in the cohort; Viral: viral etiology; ALD: Alcoholic liver disease; Varices: Percentage of patients with any 
type of varices; VNT: varices needing treatment (large varices); EGD: Esophagogastroduodenoscopy. 
§ Percentage of varices and VNT missed by applying the Baveno VI criteria: n varices/total n patients 
&Percentage of patients within the Baveno VI criteria in which endoscopy could be spared. 
% 
Silva [86] 112 80% 7% 48% 15% 1.8% 0 11% 43% 
Cales[87] 287 26% 
64
% 
44% 17% 2% 0 16.5% 41.5% 
Ahmed [88] 478 33% 
36
% 
- 11% - 0.5% 23% - 
Molina [89] 237 60% 
18
% 
35% 5% - 0 17% - 
Calvaruso[90] 
138
1 
100
% 
0 - 9% 5.5% 0.4% 15.6% - 
TOTAL 
456
9 
68% - 40.2% 9.6% 4.4% 0.2% 20.6% 39.8% 
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# Percentage of patients out of the Baveno VI criteria without varices in which endoscopy was unneeded. 
 
 
Table 5. Diagnostic performance of splenic stiffness measurement by elastography techniques for detecting oesophageal 
varices and large oesophageal varices. 
    Presence of EVs High-risk EVs 
STUDY, year Patient, n Elastograph
y  
CP-C 
(n) 
NAFLD/ALD, 
n 
COV, kPa Se, % Sp, 
% 
COV, kPa Se, % Sp, % 
Calvaruso, 
2013[54] 
96 TE 0 0/0 50 65 61 54 80 70 
Colecchia, 
2012[28] 100 TE 0 0/0 
41.3* 98 66    
55** 72 96    
Fraquelli, 
2014[55] 
198 TE - 0/0 65 91 80    
Sharma, 
2013[36] 
174 TE 20 -/77 40.8 94 76 54.5 76 73 
Stefanescu, 
2011[56] 
191 TE 13 -/- 46.4 84 71    
Wong, 2016[58] 
144 TE - 0/0 
21.4* 90 47    
50.5** 45 91    
Kim, 2015[59] 125 ARFI 8 -/41 3.16~ 87 60 3.40~ 79 63 
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Rizzo, 2014[60] 54 ARFI 0 0/0 3.1~ 96 88    
Takuma, 
2013[61] 
340 ARFI 21 3/45 3.18 99 60 3.30 99 63 
 
Abbreviations: NAFLD=non-alcoholic fatty liver disease; ALD=alcoholic liver disease; Se= sensitivity; Sp=specificity; COV=cut-off 
value; CP-C=Child-Pugh C; EVs=esophageal varices 
*Rule-out cut-off value 
**Rule-in cut-off value 
~ m/sec 
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